HBV Cure 2022 Scientific Programme
Scroll down and watch the videos of leading researchers deliver short, sharp updates on the latest strategies to cure Hepatitis B.
Slides may be downloaded if available
May, 2022
30
| The science of functional cure | Speaker | |
|---|---|---|
| What Can We Learn About HBV Cure From HIV | Prof. Sharon Lewin View Bio |
|
| Immunology Of HBV | Prof. Carolina Boni View Bio |
|
| DEBATE: cccdna Silencing Or Elimination? | FOR Silencing: Prof. Massimo Levrero View Bio, FOR Elimination: Dr Thomas Tu View Bio |
|
| Hepatitis B Virus DNA Integration And Functional Cure | Dr. Thomas Tu View Bio |
|
| Transcriptomics Of Functional Cure | Dr. Ram DasGupta View Bio |
|
| Q&A | – | |
|
Free Paper Session
|
||
| The Application of Long-read Sequencing Technologies to Investigate Structure and Expression of HBV Integrations | Dr. Cameron M. Soulette View Bio |
|
| HIV-1 Tat stimulates hepatitis B surface antigen expression in hepatocytes co-infected with HIV and hepatitis B virus | Dr. Wei Zhao | |
| Codons under positive selection in the S open reading frame of the genotype B2 Hepatitis B Virus | Dr. William Abbott | |
May, 2022
31
| New Antiviral Therapies | Speaker | |
|---|---|---|
| Capsid Inhibitor Overview | Prof. Man Fung Yuen View Bio |
|
| Progress in the Development in Core Inhibitors for the Treatment of Chronic Hepatitis B Infection | Dr. William Delaney View Bio |
|
| Entry Inhibitor For HBV/HDV | Prof. Pietro Lampertico View Bio |
|
| Q & A | – | |
| Update on AB-729 and AB-836, an siRNA and capsid inhibitor currently in development for the treatment of chronic hepatitis B infection | Dr. Gaston Picchio View Bio |
|
| Studying Hepatic distribution of oligonucleotides using Multimodal Imaging Techniques. | Dr. Steve Hood View Bio |
|
| Rep Achieving clearance of subviral particles with NAPs: A critical milestone for HBsAg loss and functional cure | Dr. Andrew Valliant View Bio |
|
| Short Interfering RNA JNJ-3989 based combination Therapy in Chronic Hepatitis B | Dr. Oliver Lenz View Bio |
|
| Which Antiviral Strategies For Functional Cure? An Overview | Prof. Massimo Levrero View Bio |
|
| Q&A | – |
June, 2022
1
| Immune Modulation In CHB | Speaker | |
|---|---|---|
| Lessons From HIV-HBV Co-Infection And Functional Cure: Restoration Of Immune Responses | Prof. Sharon Lewin View Bio |
|
| Immune Pathways & Mechanisms Leading To Functional Cure | Prof. Carolina Boni View Bio |
|
| The Role Of Innate Immunity In Functional Cure | Prof. Fabien Zoulim View Bio |
|
| Therapeutic Vaccination And Novel Immunotherapies For Functional Cure | Prof. Antonio Bertoletti View Bio |
|
| Gilead: HBV Cure Strategy and Portfolio | Dr. Simon Fletcher View Bio |
|
| Q & A | – | |
| Free Paper Session | ||
| Safety, PK, PD and Antiviral Activity of TLR7 Agonist RO7020531 in Patients with Chronic Hepatitis B Not Receiving Antiviral Treatment: a Phase 1 Study (TLR 7 program) | Dr. Filippo Canducci View Bio | |
| Identification and Validation of Hepatitis B Virus Host-Susceptibility Factors | Dr. Collins Oduor Owino View Bio | |
| Comprehensive immune profiling of intrahepatic environment of functionally cured chronic hepatitis B patients revealed altered adaptive immune response and emergence of innate immune responses | Dr. Atefeh Khakpoor | |
June, 2022
2
| The Future Of HBV Functional Cure | Speaker | |
|---|---|---|
| Debate: Immunotherapy Is Not Necessary For Functional Cure | For: Prof. Pei-Jer Chen View Bio Against: Prof. Antonio Bertoletti View Bio |
|
| Promising Preclinical Agents For Functional Cure | Prof. Fabien Zoulim View Bio |
|
| Which Combination Therapies For Functional Cure? | Prof. Edward Gane View Bio |
|
| Is It Necessary To Achieve Absolute HBV Cure? | Prof. Pei-Jer Chen View Bio |
|
| Q & A | – | |
| Free Paper Session | ||
| Bulevirtide monotherapy at low and high dose in patients with chronic hepatitis delta: 24-week interim data of the Phase 3 MYR301 study | Mr. Jacques YU | |
| Antiviral effects of oral farnesoid X receptor agonist vonafexor combined with pegylated interferon alpha2a in untreated patients with chronic hepatitis B | Dr. Bettina Hansen | |